Vanda Pharmaceuticals has named James Kelly as senior vice president (SVP), chief financial officer (CFO), treasurer and secretary of the company. Kelly has more than 18 years of experience in financial and operating roles within the healthcare and pharmaceutical industry, most recently as vice president, controller at MedImmune. He will join Vanda on 13 December 2010.
Kelly has been a key member of MedImmune’s financial leadership team since 2006. He joined MedImmune as director of sales and marketing finance and progressed to the role of vice president, controller. Prior to MedImmune and beginning in 2000, Kelly was at Biogen Idec serving in research and development finance roles of increasing responsibility, most recently as the director of planning and operations. In that role, he was the finance leader for the global development organisation and head of business operations for clinical functions.
Kelly is a CFA charterholder and a member of the Association of Bioscience Financial Officers (ABFO). He received his MBA degree from Cornell University and his BSc degree in Business Administration from the University of Vermont.
A report by broking group Marsh examines the repercussions from the administration of the South Korean company, which filed for bankruptcy protection at the end of August.
Global research by C2FO suggests that smaller businesses are less concerned with the repercussions of Brexit and the upcoming US presidential election.
A squeeze on skilled talent means it now takes an average of seven weeks to fill open permanent roles in finance in the UK according to new research from financial services recruitment firm Robert Half.
Early-stage merger and acquisition deals in Asia-Pacific show nearly 10% year-on-year growth in recent months.